COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC.Ensysce Biosciences, Inc. • November 9th, 2023 • Pharmaceutical preparations
Company FiledNovember 9th, 2023 IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ________ [ ], 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 17th, 2023 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 17th, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of May 10, 2023, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 24th, 2023 • Ensysce Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 24th, 2023 Company IndustryThis Registration Rights Agreement (this “Agreement”) is made and entered into as of October [*], 2023 between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
WARRANT AGREEMENTWarrant Agreement • December 5th, 2017 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledDecember 5th, 2017 Company Industry JurisdictionTHIS WARRANT AGREEMENT (this “Agreement”), dated as of December 1, 2017, is by and between Leisure Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”, also referred to herein as the “Transfer Agent”).
COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC.Ensysce Biosciences, Inc. • February 14th, 2024 • Pharmaceutical preparations • New York
Company FiledFebruary 14th, 2024 Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [August 14, 2025 / May 12, 2028] (the “Termination Date”), but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), up to ________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
FORM OF INDEMNITY AGREEMENTForm of Indemnity Agreement • November 3rd, 2017 • Leisure Acquisition Corp. • Blank checks • Delaware
Contract Type FiledNovember 3rd, 2017 Company Industry JurisdictionTHIS INDEMNITY AGREEMENT (this “Agreement”) is made as of [●], 2017, by and between LEISURE ACQUISITION CORP., a Delaware corporation (the “Company”), and [●] (“Indemnitee”).
SENIOR SECURED CONVERTIBLE NOTE DUE APRIL [*], 2024Ensysce Biosciences, Inc. • October 24th, 2023 • Pharmaceutical preparations • Nevada
Company FiledOctober 24th, 2023 Industry JurisdictionTHIS SENIOR SECURED CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Senior Secured Convertible Notes of Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), having its principal place of business at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California, 92037 , designated as its Senior Secured Convertible Note due April [*], 2024 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 24th, 2023 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledOctober 24th, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of October 23, 2023, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITY AGREEMENTSecurity Agreement • October 24th, 2023 • Ensysce Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 24th, 2023 Company IndustryThis SECURITY AGREEMENT, dated as of October [*], 2023 (this “Agreement”), is among Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”), the holders of the Company’s Senior Secured Convertible Notes due six (6) months following their dates of issuance, in the original aggregate principal amount of at least $1,500,000 (collectively, the “Notes”) signatory hereto, their endorsees, transferees and assigns (collectively, the “Secured Parties”) and 3I, LP, in its capacity as agent for the Secured Parties (“Agent”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • December 5th, 2017 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledDecember 5th, 2017 Company Industry JurisdictionThis Investment Management Trust Agreement (this “Agreement”) is made effective as of December 1, 2017 by and between Leisure Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC.Ensysce Biosciences, Inc. • February 14th, 2024 • Pharmaceutical preparations • New York
Company FiledFebruary 14th, 2024 Industry JurisdictionTHIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 12, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), up to _____ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated as of December 14, 2023.
SUBSIDIARY GUARANTEESubsidiary Guarantee • July 6th, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 6th, 2022 Company Industry JurisdictionSUBSIDIARY GUARANTEE, dated as of June 30, 2022 (this “Guarantee”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”), in favor of the purchasers signatory (together with their permitted assigns, the “Purchasers”) to that certain Securities Purchase Agreement, dated as of the date hereof, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”) and the Purchasers.
FORM OF REGISTRATION RIGHTS AGREEMENTForm of Registration Rights Agreement • November 28th, 2017 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledNovember 28th, 2017 Company Industry JurisdictionTHIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [_______], 2017, is made and entered into by and among Leisure Acquisition Corp., a Delaware corporation (the “ Company”), Hydra Management, LLC (“Hydra Sponsor”), Matthews Lane Capital Partners LLC (“MLCP Sponsor” and collectively with Hydra Sponsor, the “Sponsors”), HG Vora Special Opportunities Master Fund, Ltd. (the “Strategic Investor”) and the undersigned parties listed under Holders on the signature page hereto (each such party, together with the Sponsors, the Strategic Investor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement, a “Holder” and collectively the “Holders”).
PREFUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC.Ensysce Biosciences, Inc. • August 30th, 2024 • Pharmaceutical preparations
Company FiledAugust 30th, 2024 IndustryTHIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 6th, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 6th, 2022 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2022, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 5th, 2017 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledDecember 5th, 2017 Company Industry JurisdictionTHIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 1, 2017, is made and entered into by and among Leisure Acquisition Corp., a Delaware corporation (the “ Company”), Hydra Management, LLC (“Hydra Sponsor”), Matthews Lane Capital Partners LLC (“MLCP Sponsor” and collectively with Hydra Sponsor, the “Sponsors”), HG Vora Special Opportunities Master Fund, Ltd. (the “Strategic Investor”) and the undersigned parties listed under Holders on the signature page hereto (each such party, together with the Sponsors, the Strategic Investor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement, a “Holder” and collectively the “Holders”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 30th, 2024 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 30th, 2024 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of August 28, 2024, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AMENDMENT NO. 1 TO TRANSACTION SUPPORT AGREEMENTWarrant Agreement • January 31st, 2020 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledJanuary 31st, 2020 Company Industry JurisdictionThis Amendment No. 1 (this “Amendment”) to that certain Transaction Support Agreement (as defined below) is made and entered into as of January 30, 2020, by and among the Persons set forth on Schedule I hereto (each, a “Supporting Party” and together, the “Supporting Parties”), Leisure Acquisition Corp., a Delaware corporation (“LACQ”) and GTWY Holdings Limited, a Canadian corporation (the “Company”).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • March 15th, 2021 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledMarch 15th, 2021 Company Industry JurisdictionThis SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of the date first above written by and among ENSYSCE BIOSCIENCES, INC., a Delaware corporation and having a principal place of business at 7946 Ivanhoe Ave, Ste 201, La Jolla, CA 92037 (the “Company”); GEM GLOBAL YIELD LLC SCS, a “societe en commandite simple” formed under the laws of Luxembourg having LEI No. 213800CXBEHFXVLBZO92 having an address at 412F, Route d’Esch, L-2086 Luxembourg (the “Purchaser”); and GEM YIELD BAHAMAS LIMITED, a limited company formed under the laws of the Commonwealth of the Bahamas and having an address at 3 Bayside Executive Park, West Bay Street & Blake Road, P.O. Box N-4875, Nassau, The Bahamas (“GYBL,” and together with the Company and Purchaser, the “Parties”).
Leisure Acquisition Corp. 250 West 57th Street, Suite 2223 New York, NY 10107Leisure Acquisition Corp. • October 3rd, 2017 • Blank checks • New York
Company FiledOctober 3rd, 2017 Industry JurisdictionWe are pleased to accept the offer Hydra Management, LLC (the “Subscriber” or “you”) has made to purchase 297,500 shares of common stock (the “Shares”), par value $0.0001 per share (the “Common Stock”), which are subject to complete or partial forfeiture by you if the underwriters of the initial public offering (“IPO”) of units of Leisure Acquisition Corp., a Delaware corporation (the “Company”), do not fully exercise their over-allotment option (the “Over-allotment Option”) or otherwise pursuant to Sections 3.2. The terms (this “Agreement”) on which the Company is willing to sell the Shares to the Subscriber, and the Company and the Subscriber’s agreements regarding such Shares, are as follows:
WARRANT PURCHASE AGREEMENTWarrant Purchase Agreement • December 5th, 2017 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledDecember 5th, 2017 Company Industry JurisdictionTHIS WARRANT PURCHASE AGREEMENT, dated as of December 1, 2017 (as it may from time to time be amended and including all schedules referenced herein, this “Agreement”), is entered into by and between Leisure Acquisition Corp., a Delaware corporation (the “Company”), and each of the purchasers that are signatories hereto (each, a “Purchaser” and collectively, (the “Purchasers”).
AMENDMENT NO. 4 TO THE INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • November 30th, 2020 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledNovember 30th, 2020 Company Industry JurisdictionThis Amendment No. 4 (this “Amendment”) to the Investment Management Trust Agreement is made as of November 30, 2020 by and between Leisure Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”). All terms used but not defined herein shall have the meanings assigned to them in the Trust Agreement.
LETTER AGREEMENTLetter Agreement • December 5th, 2017 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledDecember 5th, 2017 Company Industry JurisdictionThis letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) proposed to be entered into by and between Leisure Acquisition Corp., a Delaware corporation (the “Company”), and Morgan Stanley & Co. LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”) of 20,000,000 of the Company’s units (the “Units”), each comprised of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and one-half of one warrant (each, a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one share of the Common Stock at a price of $11.50 per share, subject to adjustment. Only whole warrants are exercisable. The Units shall be sold in the Public Offering pursuant to a registration statement on Form S-1 (the “Registration Statement”) and prospectus (the “Prospectus”) filed by
ENSYSCE BIOSCIENCES, INC. 2,280,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 620,000 Shares of Common Stock Warrants to Purchase up to 5,800,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 8th, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledDecember 8th, 2022 Company IndustryEnsysce Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained in this Underwriting Agreement (the “Agreement”), to sell to you (the “Underwriter”), an aggregate of (i) 2,280,000 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 620,000 shares of Common Stock (the “Pre-Funded Warrant Shares”) and (iii) warrants (the “Firm Warrants”) to purchase up to an aggregate of 5,800,000 shares of Common Stock (the “Firm Warrant Shares”). The Firm Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Firm Warrants and the Firm Warrant Shares are collectively referred to as the “Firm Securities.” The Company also proposes to issue and sell to the Underwriter, upon the terms and conditions set forth herein, up to an additional (i) 342,000 shares of Common Stock (the “Option Shares”, a
SENIOR SECURED CONVERTIBLE NOTE DUE DECEMBER 29, 2023Ensysce Biosciences, Inc. • August 2nd, 2022 • Pharmaceutical preparations • Nevada
Company FiledAugust 2nd, 2022 Industry JurisdictionTHIS SENIOR SECURED CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Senior Secured Convertible Notes of Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), having its principal place of business at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California, 92037 , designated as its Senior Secured Convertible Note due December 29, 2023 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
20,000,000 Units leisure Acquisition Corp. Units, each consisting of one share of common stock, $0.0001 par value, and one-half of one warrant UNDERWRITING AGREEMENTSecurities Assignment Agreement • December 1st, 2017 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledDecember 1st, 2017 Company Industry JurisdictionLeisure Acquisition Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 20,000,000 units of the Company (the “Firm Securities”). Each unit (“Unit(s)”) consisting of one share of common stock, $0.0001 par value, of the Company (“Share(s)”) and one-half of one warrant of the Company, where each whole warrant entitles the holder to purchase one Share (the “Warrant(s)”).
EXPENSE ADVANCEMENT AGREEMENTExpense Advancement Agreement • December 5th, 2017 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledDecember 5th, 2017 Company Industry JurisdictionTHIS EXPENSE ADVANCEMENT AGREEMENT (this “Agreement”), dated as of December 1, 2017, is made and entered into by and among Leisure Acquisition Corp., a Delaware corporation (the “Company”), Hydra Management, LLC (“Hydra”), MLCP GLL Funding LLC (“MLCP”) and HG Vora Special Opportunities Master Fund, Ltd. (“HG Vora” and together with Hydra and MLCP, the “Funding Parties”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 7th, 2021 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 7th, 2021 Company Industry JurisdictionThis Indemnification Agreement, dated as of June 30, 2021, is made by and between Ensysce Biosciences, Inc., a Delaware corporation and [●], an individual.
EXCHANGE AGREEMENTExchange Agreement • June 9th, 2021 • Leisure Acquisition Corp. • Pharmaceutical preparations • New York
Contract Type FiledJune 9th, 2021 Company Industry JurisdictionWHEREAS, the Warrantholder is the holder of Private Placement Warrants (as defined in the Warrant Agreement dated as of December 1, 2017 between the Company and Continental Stock Transfer and Trust Company (the “Warrant Agreement’)) and/or other private warrants issued or which will be issued by the Company at or prior to the consummation of the business combination by Ensysce Biosciences, Inc. which have the same terms and conditions as the Private Placement Warrants issued pursuant to the Warrant Agreement (collectively, the “Old Private Warrants”);
AMENDMENT NO. 4Expense Advancement Agreement • February 25th, 2021 • Leisure Acquisition Corp. • Blank checks • New York
Contract Type FiledFebruary 25th, 2021 Company Industry JurisdictionThis Amendment No. 4 to the Expense Advancement Agreement (the “Amendment”) is entered into as of February 23, 2021 by and among Leisure Acquisition Corp., a Delaware corporation (the “Company”), Hydra Management, LLC (“Hydra”), MLCP GLL Funding LLC (“MLCP”) and HG Vora Special Opportunities Master Fund, Ltd. (“HG Vora” and together with Hydra and MLCP, the “Funding Parties”).
ENSYSCE BIOSCIENCES, INC. AMENDED AND RESTATED 2021 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE ANDAward Agreement • March 31st, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 31st, 2022 Company Industry JurisdictionEnsysce Biosciences, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Amended and Restated Omnibus Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option to purchase the number of shares of Common Stock (the “Shares”) set forth below (the “Option”). The Option described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the terms and conditions set forth in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings defined in the Plan.
July 22, 2021 Geoff Birkett Chadds Ford, Pa Via email: gbirkett@ensysce.com Dear Geoff:Separation Agreement • October 29th, 2021 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • Texas
Contract Type FiledOctober 29th, 2021 Company Industry JurisdictionEnsysce Biosciences, Inc. (the “Company”) is pleased confirm its offer of employment to you on the terms and subject to the conditions set forth in this letter agreement (this “Agreement”).
Leisure Acquisition Corp. 250 West 57th Street, Suite 2223 New York, NY 10107Leisure Acquisition Corp. • November 3rd, 2017 • Blank checks • New York
Company FiledNovember 3rd, 2017 Industry JurisdictionWe are pleased to accept the offer HG Vora Special Opportunities Master Fund, Ltd. (the “Subscriber” or “you”) has made to purchase 2,845,000 shares of common stock (the “Shares”), par value $0.0001 per share (the “Common Stock”), which are subject to complete or partial forfeiture by you if the underwriters of the initial public offering (“IPO”) of units of Leisure Acquisition Corp., a Delaware corporation (the “Company”), do not fully exercise their over-allotment option (the “Over-allotment Option”) or otherwise pursuant to Sections 3.2 or 3.3. The terms (this “Agreement”) on which the Company is willing to sell the Shares to the Subscriber, and the Company and the Subscriber’s agreements regarding such Shares, are as follows:
CONSULTING AGREEMENTConsulting Agreement • April 16th, 2021 • Leisure Acquisition Corp. • Pharmaceutical preparations • California
Contract Type FiledApril 16th, 2021 Company Industry JurisdictionTHIS CONSULTING AGREEMENT (the “Agreement”), is made and entered into as of the 4th day of August, 2020, by and between PETER COLE (“Consultant”), and COVISTAT, INC., a Delaware corporation (“Client”) (Consultant and Client are sometimes collectively referred to as the “parties” and each individually as a “party”).
Certain bracketed information in Appendix B to this Exhibit has been excluded because it is both not material and is the type that the registrant treats as private or confidential]Ensysce Biosciences, Inc. • September 22nd, 2021 • Pharmaceutical preparations
Company FiledSeptember 22nd, 2021 Industry